HANS BIOMED CORPORATION: debt-to-equity, ROE and more
KOSDAQ, Legal name HANS BIOMED CORPORATION
Latest figures are the FY2025 consolidated summary statements.
Latest fiscal year ratios (computed here)
- Debt/equity
- 273.0%
- Equity ratio
- 26.8%
- ROE
- -94.7%
- Op. margin
- -28.8%
- Rev. growth
- 10.7%
- Interest coverage
- n/a
Condition flags
- Latest operating profit is not above zero, or not reported.
- Operating loss for 1 straight year.
- Total equity is above paid-in capital. Not capital-impaired.
Interest coverage and dividends (OpenDART)
Interest expense and dividends come from DART's OpenDART annual-report filings, not the FSC summary statements used above. The source differs from the other tables on this page.
Interest coverage = operating profit ÷ interest expenseNo interest expense value yet for this company. Most companies fold interest expense into a single finance-costs line on their income statement, so it cannot be pulled out separately. Interest coverage is not computed here.
Dividends, last 3 fiscal years
No dividend data yet for this company.
Source values from the OpenDART (금융감독원 전자공시) annual report. Report fiscal year 2025.
Ratios by year (computed here)
Debt-to-equity = total liabilities ÷ total equity × 100Equity ratio = total equity ÷ total assets × 100ROE = net income ÷ year-end total equity × 100Operating margin = operating profit ÷ revenue × 100Revenue growth = (this year − last year) ÷ last year × 100
Computed from the source figures above with these formulas. Where the source's own debt-to-equity differs from ours, both are shown for that year.
| Fiscal year | Debt/equity | Equity ratio | ROE | Op. margin | Rev. growth |
|---|---|---|---|---|---|
| FY2021 consolidated | 172.0% | 36.8% | -46.5% | -33.5% | n/a |
| FY2022 consolidated | 177.5% | 36.0% | 10.4% | 1.7% | 26.0% |
| FY2023 consolidated | 145.0% | 40.8% | -48.2% | -5.3% | 4.8% |
| FY2024 consolidated | 81.3% | 55.1% | -11.6% | 0.8% | 4.0% |
| FY2025 consolidated | 273.0% | 26.8% | -94.7% | -28.8% | 10.7% |
Source figures (FSC summary statements)
Amounts are the source values, shortened. A cell reported as zero may be blank in the source, so it is not used in any ratio.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | ₩59.1B | ₩74.5B | ₩78.0B | ₩81.1B | ₩89.8B |
| Operating profit | -₩19.8B | ₩1.3B | -₩4.2B | ₩625.6M | -₩25.9B |
| Pre-tax income | -₩21.6B | ₩3.5B | -₩23.5B | -₩6.6B | -₩29.8B |
| Net income | -₩22.1B | ₩4.9B | -₩24.1B | -₩7.8B | -₩32.1B |
| Total assets | ₩129.4B | ₩131.7B | ₩122.4B | ₩121.7B | ₩126.4B |
| Total liabilities | ₩81.9B | ₩84.2B | ₩72.4B | ₩54.6B | ₩92.5B |
| Total equity | ₩47.6B | ₩47.5B | ₩49.9B | ₩67.1B | ₩33.9B |
| Paid-in capital | ₩5.1B | ₩5.1B | ₩6.1B | ₩6.8B | ₩6.8B |
| Debt/equity (source value) | 172.0% | 177.5% | 145.0% | 81.3% | 273.0% |
Company outline (FSC)
- Market
- KOSDAQ
- Fiscal year end
- Sep
- Founded
- 1999-09-15
- Listed
- 09/10/09
- Employees
- 289
- Auditor
- 삼일회계법인
- Audit opinion
- 적정의견
- Corporate reg. no.
- 1101111773872
- Outline updated
- 2026-09-24
Check the original filings
Read the annual report and audit report before you decide anything. The link opens a DART search for this company's name.
Search DART for 한스바이오메드Computed from the Financial Services Commission's company outline and summary statements (data.go.kr). Data as of 2026-09-24.